AI Article Synopsis

  • Researchers identified that the cytoplasmic domain of HIV-1's TMgp41 subunit interacts with Luman, a transcription factor influenced by intramembrane proteolysis.
  • This interaction reduces the stability of Luman, and when an active version is overexpressed, it results in decreased levels of viral proteins and virion release in HIV-1-infected cells.
  • The findings suggest that Luman negatively impacts HIV-1 production by inhibiting Tat transactivation, highlighting its role in regulating key viral proteins.

Article Abstract

In our search for new partners of the HIV-1 envelope glycoprotein (Env), we found that the cytoplasmic domain of the TMgp41 (TMgp41 CD) subunit of HIV-1 Env interacted with Luman, a transcription factor of the CREB/ATF family. Luman is anchored in the endoplasmic reticulum membrane and subjected to activation by regulated intramembrane proteolysis (RIP). The RIP process permits the release of the activated amino-terminal fragment of Luman into the cytoplasm, and its import into the nucleus. Here, we demonstrate that interaction between the TMgp41 CD and Luman requires a region encompassing the b-Zip and TM domains of Luman and decreases the stability of this factor. Moreover, we found that overexpression of a constitutively active form of Luman in cells transfected with HXB2R HIV-1 provirus decreased the intracellular expression of Gag and Env and led to a decrease in virion release. This negative effect of activated Luman on HIV-1 production was correlated to the inhibition of Tat transactivation of the HIV-1 LTR, which might be related to an interaction of activated Luman with Tat. Altogether, these results show that Luman acts as a partner of two major HIV-1 proteins: the TMgp41 Env subunit and Tat. The interaction between the TMgp41 subunit of Env and Luman affects the stability of the full-length Luman protein, the precursor of the activated, nuclear form of Luman, which acts negatively on Tat-mediated HIV-1 transactivation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2006.09.080DOI Listing

Publication Analysis

Top Keywords

luman
13
hiv-1
9
hiv-1 ltr
8
tmgp41 subunit
8
interaction tmgp41
8
form luman
8
activated luman
8
luman acts
8
tmgp41
6
env
5

Similar Publications

Introduction: Individuals with ADHD continue to face stigma, which can negatively impact their access to, adherence to, and quality of mental health services, as well as their overall wellbeing. Perspectives of various stakeholders regarding priorities for stigma reduction remain underexplored. This study explores young adult, parent, teacher, and mental health care professional perspectives on unmet needs of children and young adults with ADHD in the Netherlands, in the context of stigma reduction.

View Article and Find Full Text PDF

Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD.

View Article and Find Full Text PDF
Article Synopsis
  • * Using both animal models (Sprague Dawley rats) and cell lines (BV-2 cells), researchers assessed how paeoniflorin impacts pain-related responses and inflammation markers, noting significant reductions in pain and inflammatory proteins.
  • * Results indicate that paeoniflorin relieves neuropathic pain by modulating interactions between microglia and astrocytes through specific pathways (HSP90AA1/HMGB1), highlighting its potential as a treatment option for neuropathic pain.
View Article and Find Full Text PDF

Placebo-related improvement with methylphenidate treatment in children with ADHD.

Eur Child Adolesc Psychiatry

August 2024

VU Amsterdam, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands.

Non-specific effects of methylphenidate treatment, including expectancy and regression to the mean effects, contribute to the overall effect of methylphenidate on attention-deficit/hyperactivity disorder (ADHD) symptoms. Knowledge on the extent to which non-specific effects contribute to the overall effect and whether regression to the mean explains part of the non-specific effects, is currently lacking. A double-blind, randomized, placebo-controlled, cross-over trial was used to compare parent and teacher ratings of child ADHD symptoms at baseline and during treatment with placebo and 5, 10, 15 and 20 mg of methylphenidate, twice daily.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!